Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Kava Kava in Generalized Anxiety Disorder
NCT00083980Phase 2Terminated
- Sponsor
- National Center for Complementary and Integrative Health
- Start
- Jun 2002
- Primary completion
- Jun 2004
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of kava in generalized anxiety disorder (GAD) (3 arms), sponsored by National Center for Complementary and Integrative Health. Primary endpoint: Hamilton Anxiety Scale at 8 weeks. Started Jun 2002; status: terminated.
02
Drugs
kava
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on NCT00083980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083980.